Testing several treatments, including efgartigimod and empasiprubart, in adults with myasthenia gravis
Tests the safety and effects of different treatments in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Key facts
- Where
- Amherst, Austin, Boston, Carlsbad, Chapel Hill, Chattanooga, Cincinnati, Columbus, Detroit, Durham, Las Vegas, Miami, San Antonio, and Tampa, United StatesSee the 14 sites
Where in United States
- Dent Neurologic Institute - AmherstAmherst, United StatesTaking people
- National Neuromuscular Research InstituteAustin, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- Profound Research LLC - CarlsbadCarlsbad, United StatesTaking people
- University of North Carolina at Chapel Hill-170 Manning Dr.Chapel Hill, United StatesTaking people
- Erlanger Health SystemChattanooga, United StatesTaking people
- University of Cincinnati Medical Center - Goodman StCincinnati, United StatesTaking people
- Ohio State Martha Morehouse Outpatient CareColumbus, United StatesTaking people
- Henry Ford Health SystemDetroit, United StatesTaking people
- Duke Early Phase Clinical Research Unit - PPDSDurham, United StatesTaking people
- Profound Research LLC at Las Vegas Neurology CenterLas Vegas, United StatesTaking people
- Visionary Investigators NetworkMiami, United StatesTaking people
- University of Texas- San Antonio - Health Science Center - PPDSSan Antonio, United StatesTaking people
- University of South FloridaTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- argenx
- Trial code
- NCT07294170
- Record updated
- 26 October 2026
- Original description
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.Read full original descriptionShow less
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Inclusion: Is at least 18 years of age and the local legal age of consent for clinical studies; Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment; If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening.
Exclusion: Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk; Is MGFA (Myasthenia Gravis Foundation of America) Class V.